Company Description

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.

It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania

Palvella Therapeutics, Inc.

Country	United States
Founded	2015
Industry	Biotechnology
Sector	Healthcare
Employees	14
CEO	Wesley Kaupinen

Contact Details

Address: 125 Strafford Avenue, Suite 360 Wayne, Pennsylvania 19087 United States
Phone	484 253 1461
Website	palvellatx.com

Stock Details

Ticker Symbol	PVLA
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001742961
CUSIP Number	697947109
ISIN Number	US6979471090
Employer ID	81-2228053
SIC Code	2834

Key Executives

Name	Position
Wesley H. Kaupinen	Founder, President, Chief Executive Officer and Director
Kathleen Goin	Chief Operating Officer
Dr. Jeffrey Martini Ph.D.	Chief Scientific Officer
Matthew E. Korenberg	Chief Financial Officer and Treasurer
Bohan Wei	Vice President of Corporate Development and New Product Planning
Emily Cook	Senior Vice President of Clinical Operations
Jason Burdette	SVice President of CMC and Technical Operations
Ashley Kline	Chief Commercial Officer

Latest SEC Filings

Date	Type	Title
Dec 30, 2022	D	Notice of Exempt Offering of Securities
Jun 3, 2020	D	Notice of Exempt Offering of Securities
Aug 12, 2019	D/A	Filing
Apr 12, 2019	D	Notice of Exempt Offering of Securities
Jun 14, 2018	D	Notice of Exempt Offering of Securities

View All SEC Filings